Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Quantification of Pathologic Air Trapping in Lung Transplant Patients Using CT Density Mapping: Comparison with Other CT Air Trapping Measures.

Solyanik O, Hollmann P, Dettmer S, Kaireit T, Schaefer-Prokop C, Wacker F, Vogel-Claussen J, Shin HO.

PLoS One. 2015 Oct 2;10(10):e0139102. doi: 10.1371/journal.pone.0139102. eCollection 2015.

2.

Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis.

Cho MH, McDonald ML, Zhou X, Mattheisen M, Castaldi PJ, Hersh CP, Demeo DL, Sylvia JS, Ziniti J, Laird NM, Lange C, Litonjua AA, Sparrow D, Casaburi R, Barr RG, Regan EA, Make BJ, Hokanson JE, Lutz S, Dudenkov TM, Farzadegan H, Hetmanski JB, Tal-Singer R, Lomas DA, Bakke P, Gulsvik A, Crapo JD, Silverman EK, Beaty TH; NETT Genetics, ICGN, ECLIPSE and COPDGene Investigators.

Lancet Respir Med. 2014 Mar;2(3):214-25. doi: 10.1016/S2213-2600(14)70002-5. Epub 2014 Feb 7.

3.

Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication.

Blasi F, Tarsia P, Mantero M, Morlacchi LC, Piffer F.

Ther Clin Risk Manag. 2013;9:55-64. doi: 10.2147/TCRM.S41131. Epub 2013 Feb 12.

4.

Health effects of the Federal Bureau of Prisons tobacco ban.

Martin SA, Celli BR, DiFranza JR, Krinzman SJ, Clarke JG, Beam H, Howard S, Foster M, Goldberg RJ.

BMC Pulm Med. 2012 Oct 15;12:64. doi: 10.1186/1471-2466-12-64.

5.

Functional characterization of the matrix metalloproteinase-1 cigarette smoke-responsive region and association with the lung health study.

Wallace AM, Mercer BA, He J, Foronjy RF, Accili D, Sandford AJ, Paré PD, D'Armiento JM.

Respir Res. 2012 Sep 19;13:79. doi: 10.1186/1465-9921-13-79.

6.

Quantitative computed tomography in COPD: possibilities and limitations.

Mets OM, de Jong PA, van Ginneken B, Gietema HA, Lammers JW.

Lung. 2012 Apr;190(2):133-45. doi: 10.1007/s00408-011-9353-9. Epub 2011 Dec 17. Review.

7.

Adverse health consequences in COPD patients with rapid decline in FEV1--evidence from the UPLIFT trial.

Kesten S, Celli B, Decramer M, Liu D, Tashkin D.

Respir Res. 2011 Sep 28;12:129. doi: 10.1186/1465-9921-12-129.

8.

The relationship between lung function impairment and quantitative computed tomography in chronic obstructive pulmonary disease.

Mets OM, Murphy K, Zanen P, Gietema HA, Lammers JW, van Ginneken B, Prokop M, de Jong PA.

Eur Radiol. 2012 Jan;22(1):120-8. doi: 10.1007/s00330-011-2237-9. Epub 2011 Aug 12.

9.

Relationship of emphysema and airway disease assessed by CT to exercise capacity in COPD.

Diaz AA, Bartholmai B, San José Estépar R, Ross J, Matsuoka S, Yamashiro T, Hatabu H, Reilly JJ, Silverman EK, Washko GR.

Respir Med. 2010 Aug;104(8):1145-51. doi: 10.1016/j.rmed.2010.02.023. Epub 2010 Apr 10.

10.

Cluster analysis in severe emphysema subjects using phenotype and genotype data: an exploratory investigation.

Cho MH, Washko GR, Hoffmann TJ, Criner GJ, Hoffman EA, Martinez FJ, Laird N, Reilly JJ, Silverman EK.

Respir Res. 2010 Mar 16;11:30. doi: 10.1186/1465-9921-11-30.

11.

Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities.

Hersh CP.

Pharmacogenomics. 2010 Feb;11(2):237-47. doi: 10.2217/pgs.09.176. Review.

12.

Development of predictive models for airflow obstruction in alpha-1-antitrypsin deficiency.

Castaldi PJ, DeMeo DL, Kent DM, Campbell EJ, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard SI, Stocks JM, Stoller JK, Strange C, Turino G, Sandhaus RA, Griffith JL, Silverman EK.

Am J Epidemiol. 2009 Oct 15;170(8):1005-13. doi: 10.1093/aje/kwp216. Epub 2009 Sep 2.

Supplemental Content

Support Center